Furthermore, the combination of atezolizumab, an anti-PD-L1 agent, with bevacizumab has emerged as the established first-line therapy for advanced HCC, supported by the demonstrated efficacy of this treatment regimen [21,100]. Here, CD274 is linked to hepatocellular carcinoma.